Disease · MONDO_0005021
dilated cardiomyopathy
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. dilated cardiomyopathy. Diseases, record MONDO_0005021. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005021
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
CCM - Congestive cardiomyopathy, COCM - Congestive cardiomyopathy, Cardiomyopathies, Congestive, Cardiomyopathies, Dilated, Cardiomyopathies, Familial Idiopathic, Cardiomyopathy, Congestive, Cardiomyopathy, Dilated, CMD1A, Cardiomyopathy, Dilated, LMNA, Cardiomyopathy, Dilated, with Conduction Deffect1, Cardiomyopathy, Familial Idiopathic, Cardiomyopathy, dilated, Congestive Cardiomyopathies, Congestive cardiomyopathy, Congestive cardiomyopathy (disorder), Congestive dilated cardiomyopathy, DCM, DCM - Dilated cardiomyopathy, Dilated Cardiomyopathies, Familial Idiopathic Cardiomyopathies, Familial Idiopathic Cardiomyopathy, Idiopathic Cardiomyopathies, Familial, Idiopathic Cardiomyopathy, Familial, Primary dilated cardiomyopathy, Stretched and thinned heart muscle, primary dilated cardiomyopathy (disorder)
- Open Targets
- Highest stage of its drugs
- Phase 3, for 8 of its 29 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs29
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ARRY-797 | CHEMBL1088750 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 3 | 3 | Drugs and targets |
| IXMYELOCEL-T | CHEMBL2108733 | Cell | Phase 3 | TTD | 3 | 2 | 2 | Drugs and targets |
| BROMOCRIPTINE | CHEMBL493 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ENALAPRILAT | CHEMBL3989406 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EPLERENONE | CHEMBL1095097 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ROSUVASTATIN | CHEMBL1496 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SOMATROPIN | CHEMBL1201621 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EMPRUMAPIMOD | CHEMBL4802251 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| FILGRASTIM | CHEMBL1201567 | Protein | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| LENOGRASTIM | CHEMBL2109128 | Protein | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
1 to 10 of 29
See all 29 drugsTargets28
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB1 | Adrenergic receptor beta | 5 | Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor beta | 3 | Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist | Phase 1/2 | https://conductscience.org/library/genes/154 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 3 | HMG-CoA reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 2 | Angiotensin-converting enzyme inhibitor | Phase 3 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB3 | Adrenergic receptor beta | 1 | Adrenergic receptor beta antagonist | Unknown | https://conductscience.org/library/genes/155 | Drugs and targets |
| DRD2 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
1 to 10 of 28
See all 28 targetsTrials24
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03439514 | A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation | Phase 3 | 77 | 2024-01-09 | Dilated Cardiomyopathy, Lamin A/C Gene Mutation | ARRY-797 | Its record names the disease | ClinicalTrials.gov |
| NCT04572893 | Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities | Phase 2 | 41 | 2025-05-21 | Primary Familial Dilated Cardiomyopathy | DANICAMTIV | Its record names the disease | ClinicalTrials.gov |
| NCT00741156 | The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution | Phase 3 | 12 | 2015-12-18 | Hypertension, Congestive Cardiomyopathy | ENALAPRILAT | Its record names the disease | ClinicalTrials.gov |
| NCT02351856 | A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy | Phase 2 | 8 | 2022-03-31 | LMNA-Related Dilated Cardiomyopathy | ARRY-797 | Its record names the disease | ClinicalTrials.gov |
| NCT07210723 | A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Phase 2/3 | 332 | Symptomatic Genetic Dilated Cardiomyopathy | DANICAMTIV | Its record names the disease | ClinicalTrials.gov | |
| NCT06632834 | Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation | Phase 2 | 230 | Dilated Cardiomyopathy | SIMVASTATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06250257 | Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age | Phase 3 | 112 | Dilated Cardiomyopathy | BROMOCRIPTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02654678 | Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril | Phase 2/3 | 100 | Heart Failure, Dilated Cardiomyopathy, Congenital Heart Disease | ENALAPRIL | Its record names the disease | ClinicalTrials.gov | |
| NCT05193838 | Effect of Allopurinol on Left Ventricular Function in Children With Dilated Cardiomyopathy | 100 | Dilated Cardiomyopathy | ALLOPURINOL | Its record names the disease | ClinicalTrials.gov | ||
| NCT01857856 | PHOspholamban RElated CArdiomyopathy STudy - Intervention | Phase 3 | 84 | Phospholamban R14del Mutation-related Cardiomyopathy | EPLERENONE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 24
See all 24 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| PF-07265803 (ARRY-371797) vs Placebo: deaths from any cause | 3 of 40 | 3 of 37 | 77 | NCT03439514 | Trial comparisons |
| PF-07265803 (ARRY-371797) vs Placebo: serious adverse events | 10 of 40 | 21 of 37 | 77 | NCT03439514 | Trial comparisons |
Papers from its trials37
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005021
GET https://conductscience.org/api/diseases/v1/MONDO_0005021/drugs?page=2